Business Context and Reporting Period
This Form 6-K filing by Akari Therapeutics Plc, dated September 27, 2018, reports the execution of a Securities Purchase Agreement and Registration Rights Agreement with Aspire Capital Fund, LLC. The Company, a biopharmaceutical firm focused on product candidates like Coversin, entered into these agreements on September 26, 2018, to secure a potential source of capital.
Key Financial Metrics and Transaction Details
The filing details a committed equity financing arrangement rather than reporting standard periodic financial results (revenue, profit, or cash flow).
- Committed Capital: Aspire Capital is committed to purchase up to $20.0 million of the Company's American Depositary Shares (ADSs) over a 30-month period.
- Immediate Capital Raised: The Company sold 25,000,000 Ordinary Shares ("Initial Shares") to Aspire Capital at $0.02 per share ($2.00 per ADS), generating $500,000 in immediate proceeds.
- Commitment Shares: The Company issued 30,000,000 Ordinary Shares to Aspire Capital as consideration for entering the agreement.
- Use of Proceeds: Expected to be used for working capital and general corporate purposes.
- Debt and Liquidity: The filing does not provide specific figures for total debt, cash on hand, or liquidity ratios. It notes the Company has no financial covenants or restrictions on future funding under this agreement.
Material Changes and Transaction Mechanics
The primary material change is the establishment of an "at-the-market" style sales facility with Aspire Capital.
- Pricing Mechanism: The purchase price is the lesser of the lowest sale price on the purchase date or the average of the three lowest closing prices over the preceding 10 business days. A Volume-Weighted Average Price (VWAP) option allows purchases at 97% of the VWAP.
- Sale Limits: The Company may direct sales of up to 150,000 ADSs per business day, with an additional VWAP option for up to 250,000 ADSs (capped at 30% of daily volume).
- Price Floor: No sales may occur if the closing sale price of the ADSs is less than $0.25.
- Control: The Company controls the timing and amount of sales; Aspire Capital has no right to require sales but is obligated to purchase as directed.
Outlook, Risks, and Management Commentary
Management, represented by Interim CEO Clive Richardson, highlighted the agreement as a mechanism to access capital for operations. The filing includes extensive forward-looking statements and risk disclosures.
- Going Concern: The Company explicitly lists "ability to continue as a going concern" and "uncertainties of cash flows" as material risks.
- Operational Risks: Risks include delays in regulatory approvals for Coversin, clinical trial failures, patient enrollment difficulties, and manufacturing supply chain issues.
- Legal and Governance: The filing references risks associated with a putative shareholder class action, an SEC investigation, material weaknesses in internal controls, and the departure of former executive officers.
- Termination: The Company may terminate the Purchase Agreement at any time without cost.
Investor Verification Checklist
- Verify the Company's current cash runway and specific working capital needs given the "going concern" risk disclosure.
- Confirm the status of the SEC registration statement required to activate the $20.0 million purchase commitment.
- Review the details of the referenced putative shareholder class action and SEC investigation in other filings.
- Assess the dilution impact of the 30,000,000 Commitment Shares and 25,000,000 Initial Shares issued immediately.
- Monitor the $0.25 price floor, as the Company cannot raise funds under this agreement if the stock trades below this threshold.